5 June 2015
New research has identified a highly effective biomarker in lung cancer, which could help diagnose and improve survival rates for the disease.
It is already known that spotting lung cancer in the first stages significantly improves the chance of survival. Finding biomarkers are key for detecting the disease before any symptoms present themselves.
Published in the journal Oncotarget, a new study has found a protein that circulates and appears to be more accurate at spotting non-small cell lung cancer (NSCLC) than current methods.
These findings, by a team at the Wistar Institute, will need to be confirmed by a larger trial but could lead to a blood test that is easier to use and more accurate in diagnosis.
Due to the increased accuracy, the test could also be better at distinguishing between benign lung tumours and malignant ones that can grow and spread.
Dr Qihong Huang, associate professor in the Tumor Microenvironment and Metastasis Program at the Wistar Institute and lead author of the study, said:. "If we can develop a simple blood test that's more accurate than low-dose CT scans, we can detect the cancer earlier with a less expensive, less invasive and more accurate blood test."
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.
Image Credit: AlexRaths/Thinkstock